Emergent BioSolutions (NYSE:EBS) Stock Price Down 7% – What’s Next?

Emergent BioSolutions Inc. (NYSE:EBS)’s share price was down 7% during trading on Monday . The stock traded as low as $10.12 and last traded at $10.46. Approximately 376,780 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 954,547 shares. The stock had previously closed at $11.25.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on EBS shares. Benchmark increased their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Finally, StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Friday, January 24th.

Emergent BioSolutions Stock Up 2.2 %

The stock has a 50-day moving average of $9.63 and a 200-day moving average of $9.30. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The firm has a market cap of $580.65 million, a price-to-earnings ratio of -2.61 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.88. The company had revenue of $293.80 million for the quarter, compared to analyst estimates of $328.72 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the prior year, the firm posted ($1.44) EPS. Sell-side analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Emergent BioSolutions

Large investors have recently bought and sold shares of the company. Stifel Financial Corp acquired a new stake in shares of Emergent BioSolutions during the 3rd quarter worth approximately $96,000. FORA Capital LLC acquired a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at $103,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at $141,000. Entropy Technologies LP bought a new position in shares of Emergent BioSolutions in the 3rd quarter valued at $155,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of Emergent BioSolutions during the 4th quarter worth $201,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.